GlassScriptPhysician profile
Jeffrey A Mathews
NPI 1568414894
$838.18
in general payments reported to CMS, 2019-2025
24 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.14 · 2020: $23.70 · 2021: $270 · 2022: $279 · 2023: $19.20 · 2024: $37.18 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $128 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.23 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $99.72 | 2021-2025 | Imfinzi |
| Ucb, INC. | $96.17 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.03 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $55.64 | 2021 | |
| Amgen INC. | $53.51 | 2019-2022 | |
| Neurelis, INC. | $52.49 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $50.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.34 | 2024-2025 | Gattex |
| Lilly USA, LLC | $37.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $30.21 | 2022 | |
| Esperion Therapeutics, INC. | $23.70 | 2020 | |
| Sunovion Pharmaceuticals INC. | $23.01 | 2019 | |
| Ardelyx, INC. | $22.97 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $21.75 | 2025 | Suflave |
| Kyowa Kirin, INC. | $21.23 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.20 | 2023 | Gemtesa |
| Gilead Sciences, INC. | $16.45 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.97 | 2024 | Voquezna |
| Biogen, INC. | $15.82 | 2021 | |
| Merck Sharp & Dohme LLC | $15.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.96 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.04 | 2019 | |
| Neurocrine Biosciences, INC. | $12.54 | 2022 | |
| Mylan Specialty L.P. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.